More importantly, eIF3h and Myc co-amplification markedly improve the response and survival of NSCLC patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor such as gefitinib [119]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.